XRME:F:F-Xtrackers MSCI USA ESG Screened UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 9.858

Change

+0.08 (+0.82)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.41 (+1.55%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.51 (+1.02%)

USD 108.20B
SXR8:F iShares Core S&P 500 UCITS ETF..

+5.84 (+1.10%)

USD 93.32B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.48 (+0.88%)

USD 86.92B
SXRZ:F iShares VII PLC - iShares Nikk..

+4.00 (+1.74%)

USD 53.24B
VUAA:F Vanguard S&P 500 UCITS Acc

+1.26 (+1.33%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.16 (+1.08%)

USD 51.19B
XJSE:F Xtrackers II - Japan Governmen..

-0.04 (-0.49%)

USD 41.09B
0ZC:F Zscaler Inc

+6.84 (+4.93%)

USD 37.92B

ETFs Containing XRME:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.44% 85% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.44% 83% B 66% D+
Trailing 12 Months  
Capital Gain 26.01% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.01% 81% B- 69% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.50% 77% C+ 72% C
Dividend Return 10.50% 75% C 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.76% 58% F 83% B
Risk Adjusted Return 89.32% 94% A 94% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike